Ref. No. E-038-2012
Download as PDF
Keywords: Therapeutic, cancer, HIV, viral infections, RNA switches, RNAi.
Summary: The National Cancer Institute seeks parties interested in collaborative research to co-develop therapeutic RNA switches.
Technology: Targeted therapy in cancer or viral infections is a challenge because the disease state manifests itself mainly through differences in the cell interior, for example in a form of the presence of a certain RNA or protein in the cytoplasm.
This technology, developed at the NCI Nanobiology Program, consists of designed RNA switches that activate the RNA interference pathway only in the presence of a trigger RNA or DNA to which they bind, in order to knock down a chosen gene that is not necessarily related to the initial trigger.
This new approach can lead to a new type of drug that has the unique feature of selectively causing a biochemical effect (such as apoptosis) in cells that are infected by RNA viruses (such as HIV), as well as cancer cells. The RNA switch concept can be expanded to selectively treat other genetically related diseases.
Potential Commercial Applications:
Competitive Advantages:
Development Stage: Discovery, in vitro data available
Patent Status: US Provisional Application No. 61/561,247 filed 17 Nov 2011.
Related technology: NIH Ref. # E-039-2012/0 U.S. Patent Application No. 61/561,257 filed 17 Nov 2011
Publications:
Nano Lett 11: 878-87, 2011 [PMID 21229999]
Contact: Please submit an information request form at http://techtransfer.cancer.gov/ or contact:
John Hewes, Ph.D., (301) 435-3121 hewesj@mail.nih.gov.
Created: 10/24/2012